Company: TAK
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001395064-25-000120
Chunk: 14

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-07-30
Form: 6-K
Chunk 14
---
 %                         |
| Core research and development (R&D) expenses             |     |            |     |  -168.5 |     |           |     |  -143.9 |     |          |     |   24.6 |     | -14.6 | % |     |     |  -9.7 | %                         |
| Core operating profit                                    |     |            |     |   382.3 |     |           |     |   321.8 |     |          |     |  -60.4 |     | -15.8 | % |     |     | -11.9 | %                         |

During the periods presented, these items fluctuated as follows:

#### Core Cost of Sales
Core Cost of Sales was JPY 384.9 billion (JPY -2.2 billion and -0.6% AER, +4.4% CER). The decrease was primarily due to the appreciation of the Japanese yen, partially offset by a change in product mix.

<div align='center'>7</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Three-month

Period Ended June 30, 2025 (Consolidated)

Core Selling, General and Administrative (SG&A) Expenses

Core SG&A expenses were JPY 256.0 billion (JPY -14.1 billion and -5.2% AER, -0.0% CER). The decrease was mainly due to the appreciation of the Japanese yen.

#### Core Research and Development (R&D) Expenses
Core R&D expenses were JPY 143.9 billion (JPY -24.6 billion and -14.6% AER, -9.7% CER). The decrease was mainly due to lower expenses attributable to termination of development programs and the appreciation of the Japanese yen, partially offset by higher expense on late-stage pipelines in the three-month period ended June 30, 2025.

#### Core Net Profit for the Period
Core Net Profit for the Period was JPY 237.1 billion ( JPY -39.8 billion and -14.4% AER, -10.3% CER) and Core Net Profit attributable to owners of the Company was JPY 237.0 billion (JPY -39.8 billion and -14.4% AER, -10.3% CER) and are calculated from Core